Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Truscreen Group's share price for the quarter that ended in Sep. 2024 was NZ$0.019. Truscreen Group's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 552.59 Mil. Therefore, Truscreen Group's market cap for the quarter that ended in Sep. 2024 was NZ$10.50 Mil.
Truscreen Group's quarterly market cap
increased
from Sep. 2023 (NZ$10.42 Mil) to Mar. 2024 (NZ$12.16 Mil) but then
declined
from Mar. 2024 (NZ$12.16 Mil) to Sep. 2024 (NZ$10.50 Mil).
Truscreen Group's annual market cap
declined
from Mar. 2022 (NZ$25.76 Mil) to Mar. 2023 (NZ$12.08 Mil) but then
increased
from Mar. 2023 (NZ$12.08 Mil) to Mar. 2024 (NZ$12.16 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Truscreen Group's Enterprise Value for Today is NZ$15.76 Mil.
Truscreen Group Market Cap Historical Data
The historical data trend for Truscreen Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Truscreen Group's Market Cap
For the Medical Devices subindustry, Truscreen Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Truscreen Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Truscreen Group's Market Cap for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (NZSE:TRU) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Truscreen Group Market Cap Related Terms
Thank you for viewing the detailed overview of Truscreen Group's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NZSE:TRU has been successfully added to your 